The clinical significances of irritable bowel syndrome in Taiwan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 3, 2011, Pages 102-105

  Chang, Full Young ^a   Lu, Ching Liang ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Bowel movement; Functional gastrointestinal disorder; Irritable bowel syndrome; Motility; Rome criteria

Indexed keywords

DIGESTIVE TRACT AGENT; MEBEVERINE; PEPPERMINT OIL; PINAVERIUM; SMECTITIE; TEGASEROD; UNCLASSIFIED DRUG;

ABSENTEEISM; AGORAPHOBIA; ANXIETY DISORDER; ARTICLE; CHOLINERGIC ACTIVITY; CONSTIPATION; DEPRESSION; DYSPEPSIA; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTION; HUMAN; HYSTERIA; IRRITABLE COLON; NEUROSIS; PANIC; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TAIWAN;

EID: 79953118630     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06646.x     Document Type: Article

References (49)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
3. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol. Motil. 2008; 20 (Suppl.): 121-9.
4. Lu CL, Chang FY, Lang HC etal. Gender difference on the symptoms, health seeking behavior, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment. Pharmacol. Ther. 2005; 21: 1497-505.
5. Chen YH, Lin HC. Patterns of psychiatric and physical comorbidities associated with panic disorder in a nationwide population-based study in Taiwan. Acta Psychiatr. Scand. 2011; 123: 55-61.
6. Gwee KA, Wee S, Wong ML, Png DJC. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am. J. Gastroenterol. 2004; 99: 924-31.
7. Lu CL, Chang FY, Chen CY, Luo JC, Lee SD. Significance of Rome II-defined functional constipation in Taiwan and comparison with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2006; 24: 429-38.
8. Huang CT, Liu HW, Hwang CS. The content of ambulatory family practice in Kaohsiung medical college hospital. Gaoxiong Yi Xue Ke Xue Za Zhi 1992; 8: 175-84.
9. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010; 138: 1276-85.
10. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
11. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD etal. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009; 104 (Suppl.): S1-35.
12. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J. Gastroenterol. Hepatol. 2010; 25: 691-9.
13. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77: 225-35.
14. Chang FY, Lu CL. Treatment of irritable bowel syndrome using complementary and alternative medicine. J. Chin. Med. Assoc. 2009; 72: 294-300.
15. Park DW, Lee OH, Shim SG etal. The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III. J. Neurogastroenterol. Motil. 2010; 16: 186-93.
16. Chang FY, Lu CL, Chen TS. The Current prevalence of irritable bowel syndrome in Asia. J. Neurogastroenterol. Motil. 2010; 16: 389-400.
17. Kumano H, Kaiya H, Yoshiuchi K, Yamanaka G, Sasaki T, Kuboki T. Comorbidity of irritable bowel syndrome, panic disorder and agoraphobia in a Japanese representative sample. Am. J. Gastroenterol. 2004; 99: 370-6.
18. Chang FY, Lu CL. Irritable bowel syndrome in the 21st century: perspectives from Asia or South-east Asia. J. Gastroenterol. Hepatol. 2007; 22: 4-12.
19. Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2005; 21: 663-76.
20. Lu CL, Chen CY, Lang HC etal. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment. Pharmacol. Ther. 2003; 18: 1159-69.
21. Gwee KA, Bak YT, Ghoshal UC etal. The Asian consensus on the irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010; 25: 1189-205.
22. Schlemper RJ, van der Werf SDJ, Vandenbroucke JP, Biemond I, Lambers CBHW. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand. J. Gastroenterol. 1993; 28 (Suppl.): 33-41.
23. Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003; 18: 1412-16.
24. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin. Arthritis Rheum. 2007; 36: 339-56.
25. Corazziari E, Attili AF, Angeletti C, De Santis A. Gallstones, cholecystectomy and irritable bowel syndrome (IBS) MICOL population-based study. Dig. Liver Dis. 2008; 40: 944-50.
26. Guo YJ, Ho CH, Chen SC, Yang SS, Chiu HM, Huang KH. Lower urinary tract symptoms in women with irritable bowel syndrome. Int. J. Urol. 2010; 17: 175-81.
27. Lu CL, Liu CC, Fuh JL etal. Irritable bowel syndrome and negative appendectomy: a prospective multivariable investigation. Gut 2007; 56: 655-60.
28. Lu ZY, Chen WL, Chen HC, Ou M. Irritable bowel syndrome: the bodily experiences of Taiwanese women. J. Nurs. Res. 2009; 17: 42-51.
29. Kellow J, Lee OY, Chang FY etal. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
30. Lu CL, Lang HC, Chang FY etal. Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on Rome criteria questionnaire survey assisted with endoscopic exclusion among a physical checkup population. Scand. J. Gastroenterol. 2005; 40: 402-11.
31. Su YC, Wang WM, Wang SY etal. The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000; 95: 1900-5.
32. Gerards C, Leodolter A, Glasbrenner B, Malfertheiner P. H.pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Dig. Dis. 2001; 19: 170-3.
33. Lee CT, Chuang TY, Lu CL, Chen CY, Chang FY, Lee SD. Abnormal vagal cholinergic function and psychological behaviors in irritable bowel syndrome patients with predominant bowel symptoms: a hospital-based Oriental study. Dig. Dis. Sci. 1998; 43: 1794-9.
34. Horikawa Y, Mieno H, Inoue M, Kajiama G. Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers. Scand. J. Gastroenterol. 1999; 34: 1190-5.
35. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol. Motil. 2010; 22: 293-e82.
36. Lu CL, Chen CY, Chang FY, Lee SD. The characteristics of small bowel motility in irritable bowel syndrome patients and normal humans: an Oriental study. Clin. Sci. 1998; 95: 165-9.
37. Park JH, Rhee PL, Kim HS etal. Increased beta-adrenergic sensitivity correlates with visceral hypersensitivity in patients with constipation-predominant irritable bowel syndrome. Dig. Dis. Sci. 2005; 50: 1454-60.
38. Lee YC, Wang HP, Chiu HM etal. Factors determining post-colonoscopy abdominal pain: prospective study of screening colonoscopy in 1000 subjects. J. Gastroenterol. Hepatol. 2006; 21: 1575-80.
39. Tanaka T, Manabe N, Hata J etal. Characterization of autonomic dysfunction in patients with irritable bowel syndrome using fingertip blood flow. Neurogastroenterol. Motil. 2008; 20: 498-504.
40. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2001; 15: 355-61.
41. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. 2000; 133: 136-47.
42. Lu CL, Chen CY, Chang FY, Lee SD. Effect of a calcium channel blocker and antispasmodic in diarrhea-predominant irritable bowel syndrome. J. Gastroenterol. Hepatol. 2000; 15: 925-30.
43. ®) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled trial. Dig. Liver Dis. 2007; 39: 530-6.
44. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective randomized trial. J. Gastroenterol. 1997; 32: 765-8.
45. Guarino A, Lo Vecchio A, Pirozzi MR. Clinical role of diosmectite in the management of diarrhea. Expert Opin. Drug Metab. Toxicol. 2009; 5: 433-40.
46. Chang FY, Lu CL, Chen CY, Luo JC. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J. Gastroenterol. Hepatol. 2007; 22: 2266-72.
47. Mahraoui L, Heyman M, Plique O, Droy-Lefaix MT, Desjeux JF. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. Gut 1997; 40: 339-43.
48. Franke A, Singer MV, Dumitraşcu DL. How general practitioners manage patients with irritable bowel syndrome. Data from a German urban area. Rom. J. Intern. Med. 2009; 47: 47-53.
49. Chen HH, McCutcheon H. Learning needs of Taiwanese nurses caring for patients with irritable bowel syndrome. Nurs. Health Sci. 2001; 3: 173-7.